hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing
Add bookmarkThis video presentation demonstrates how hESC derived cardiomyocytes can be a powerful approach to assessing cardiac drug liabilities. Nick Thomas describes how hESC derived Cytiva Cardiomyocytes:
• are a valid model of cardiomyocytes from the human heart
• are compatible with assays routinely used for testing cardiotoxicity
• together with high-content assays and analysis, can indicate the mechanism of toxicity of drug compounds
By entering in your information and signing in to view this video , you give the sponsor permission to contact you regarding their product.
Have Your Say
Rate this feature and give us your feedback in the comments section below
Tags:
cardiotoxicity
Human embryonic stem cell-derived
hESC
clinically predictive cardiotoxicity assays
cardiac drug liabilities
hESC derived cardiomyocytes
GE
drug safety testing
toxicity
high-content assays
Cytiva Cardiomyocytes
Nick Thomas
cell model
